Irinotecan preparation

Details Irinotecan preparation Irinotecan preparation

2005-05-31

2010-12-07

Kishore, Gollamudi S (Department: 1612)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

Reexamination Certificate

active

07846473

ABSTRACT:
Provided is an irinotecan formulation capable of supporting irinotecan and/or a salt thereof in a closed vesicle carrier at a high concentration and existing in blood for a long period of time by dramatically improved retentivity in blood compared to a conventionally known irinotecan liposome formulation. That is, an irinotecan formulation including a closed vesicle formed by a lipid membrane, in which irinotecan and/or a salt thereof is encapsulated at a concentration of at least 0.07 mol/mol (drug mol/membrane total lipid mol). There is an ion gradient between an inner aqueous phase and an outer aqueous phase in the irinotecan formulation. The closed vesicle is preferably liposome, in which only the outer surface of the liposome is preferably modified with a surface-modifying agent containing a hydrophilic polymer.

REFERENCES:
patent: 5192549 (1993-03-01), Barenolz et al.
patent: 2002/0146450 (2002-10-01), Slater et al.
patent: 2006/0193902 (2006-08-01), Tardi et al.
patent: 2007/0110798 (2007-05-01), Drummond et al.
patent: 2007/0116753 (2007-05-01), Hong et al.
patent: 1323199 (2001-11-01), None
patent: 1 190 706 (2002-03-01), None
patent: 2001-64158 (2001-03-01), None
patent: 2002-527466 (2002-08-01), None
patent: WO 95/08986 (1995-04-01), None
patent: WO 98/34597 (1998-08-01), None
patent: WO 99/15153 (1999-04-01), None
patent: WO 00/23052 (2000-04-01), None
patent: WO 01/08663 (2001-02-01), None
patent: WO 03/028697 (2003-04-01), None
patent: 03/041681 (2003-05-01), None
patent: 2004/087104 (2004-10-01), None
Yasuyuki Sadzuka et al., “Effect of Liposomalization on the Antitumor Activity, Side-Effects and Tissue Distribution of CPT-11”, Cancer Letters, 1998, vol. 127, pp. 99-105, Elsevier Science Ireland Ltd. (cited in specification).
English language version of Written Opinion of the International Searching Authority.
Chinese Office Action dated Nov. 28, 2008 issued in corresponding Chinese Application No. 2005800176008.
International Search Report dated Aug. 23, 2005.
Tzung-Han Chou et al., “Effect of Composition on the Stability of Liposomal Irinotecan Prepared by a pH Gradient Method,”Journal of Bioscience and Bioengineering, 2003 (month unknown), pp. 405-408, vol. 95, No. 4, Society of Biotechnology, Japan.
Office Action dated Aug. 13, 2009 issued in corresponding Israeli Patent Application No. 179558.
Lundberg, Bo B., et al., “Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions,”Anti-Cancer Drug Design, 1998 (month unknown), pp. 453-461, vol. 13, Oxford University Press, USA.
Office Action issued in New Zealand Patent Application No. 551748, May 7, 2009, Intellectual Property Office of New Zealand, NZ.
Search Report and Written Opinion issued in Singapore Patent Application No. 200608044-4, May 25, 2009, Intellectual Property Office of Singapore/Austrian Patent Office, Singapore/Austria.
Official Action issued in corresponding CA Patent Appln. No. 2,567,857, Apr. 30, 2008, Canadian Intellectual Property Office, CA.

Affiliated with

Also associated with

Rating

Irinotecan preparation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Irinotecan preparation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Irinotecan preparation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4175001